search
Back to results

Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy (ASPIRATE)

Primary Purpose

Acute Mountain Sickness

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Ibuprofen
Acetazolamide
Sponsored by
Grant S Lipman
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Acute Mountain Sickness

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Age 18-65 healthy non-pregnant volunteer
  2. Sea-level dwelling (live at low elevation < 4000 ft)
  3. Arrange your own transportation to WMRS (Bishop) by Friday evening of study weekend
  4. Available for full study duration (Friday PM-Sunday AM)

Exclusion Criteria:

  1. Age <18 or >65, Pregnant, Live at altitude >4000 ft
  2. Slept at altitude > 4000ft within 1 week of study
  3. Allergic to acetazolamide, sulfa drugs, or non-steroidal anti-inflammatories
  4. Taking NSAIDs, Acetazolamide, or Corticosteroids 1 week prior to study
  5. Medical History of Brain Tumor, increased brain pressure, pseudotumor cerebri, VP shunts, HACE, or HAPE.

Sites / Locations

  • White Mountain Research Station

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Ibuprofen

acetazolamide

Arm Description

ibuprofen, 600mg, three times a day, through to ascent to high altitude

acetazolamide, 125mg, two times a day, through to ascent to high altitude

Outcomes

Primary Outcome Measures

incidence of acute mountain sickness
incidence of acute mountain sickness by Lake Louise Questionnaire

Secondary Outcome Measures

severity of acute mountain sickness
severity of acute mountain sickness by Lake Louise Questionnaire (0-15)
oxygen saturation
measurement of oxygen saturation (%) by fingertip pulse oximetry
Groningen Sleep Quality Questionnaire (GSQQ)
Groningen Sleep Quality Questionnaire (GSQQ) (0-14)

Full Information

First Posted
May 11, 2017
Last Updated
November 21, 2018
Sponsor
Grant S Lipman
search

1. Study Identification

Unique Protocol Identification Number
NCT03154645
Brief Title
Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy
Acronym
ASPIRATE
Official Title
Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy
Study Type
Interventional

2. Study Status

Record Verification Date
November 2018
Overall Recruitment Status
Completed
Study Start Date
August 12, 2017 (Actual)
Primary Completion Date
October 1, 2017 (Actual)
Study Completion Date
October 1, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Grant S Lipman

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This double blind randomized trial will compare ibuprofen to acetazolamide for the prevention of acute mountain sickness. These drugs have never been directly compared for efficacy. The study population is hikers who are ascending at their own rate under their own power in a true hiking environment at the White Mountain Research Station, Owen Valley Lab (OVL) and Bancroft Station (BAR), Bancroft Peak, White Mountain, California.
Detailed Description
The specific aim of this study is to evaluate if acetazolamide will be similar to ibuprofen (i.e. Ibuprofen being non-inferior) in decreasing the incidence of Acute Mountain Sickness (AMS) in travelers to high altitude. It has been shown that ibuprofen taken 3 times a day 6 hours prior to ascent is effective for the prevention of AMS, with a number needed to treat of 4, decreasing the odds of getting AMS by a third. The efficacy appears to be similar to acetazolamide, with a NNT of 3 -8, although these two medications have not been directly compared in prevention of AMS. Acetazolamide is diuretic that is the only FDA approved AMS prophylactic medication and the most commonly used drug for AMS prevention. Although acetazolamide has been given a 1A indication, it has been shown to limit exercise capabilities at high altitude, and rapid ascent has been shown to attenuate its protective effects. Ibuprofen has been given a IIB recommendation by the Wilderness Medical Society Practice Guidelines, in part because it has not directly compared to acetazolamide. It is unknown if a non-steroidal anti-inflammatory can provide protection from AMS equivalent to acetazolamide.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Mountain Sickness

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
randomized double blind controlled trial
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
visually identical pills
Allocation
Randomized
Enrollment
92 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ibuprofen
Arm Type
Active Comparator
Arm Description
ibuprofen, 600mg, three times a day, through to ascent to high altitude
Arm Title
acetazolamide
Arm Type
Active Comparator
Arm Description
acetazolamide, 125mg, two times a day, through to ascent to high altitude
Intervention Type
Drug
Intervention Name(s)
Ibuprofen
Other Intervention Name(s)
Motrin
Intervention Description
non-steroidal anti-inflammatory drug
Intervention Type
Drug
Intervention Name(s)
Acetazolamide
Other Intervention Name(s)
diamox
Intervention Description
a diuretic
Primary Outcome Measure Information:
Title
incidence of acute mountain sickness
Description
incidence of acute mountain sickness by Lake Louise Questionnaire
Time Frame
2 days
Secondary Outcome Measure Information:
Title
severity of acute mountain sickness
Description
severity of acute mountain sickness by Lake Louise Questionnaire (0-15)
Time Frame
2 days
Title
oxygen saturation
Description
measurement of oxygen saturation (%) by fingertip pulse oximetry
Time Frame
2 days
Title
Groningen Sleep Quality Questionnaire (GSQQ)
Description
Groningen Sleep Quality Questionnaire (GSQQ) (0-14)
Time Frame
2 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age 18-65 healthy non-pregnant volunteer Sea-level dwelling (live at low elevation < 4000 ft) Arrange your own transportation to WMRS (Bishop) by Friday evening of study weekend Available for full study duration (Friday PM-Sunday AM) Exclusion Criteria: Age <18 or >65, Pregnant, Live at altitude >4000 ft Slept at altitude > 4000ft within 1 week of study Allergic to acetazolamide, sulfa drugs, or non-steroidal anti-inflammatories Taking NSAIDs, Acetazolamide, or Corticosteroids 1 week prior to study Medical History of Brain Tumor, increased brain pressure, pseudotumor cerebri, VP shunts, HACE, or HAPE.
Facility Information:
Facility Name
White Mountain Research Station
City
Bishop
State/Province
California
ZIP/Postal Code
93515
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
30419226
Citation
Burns P, Lipman GS, Warner K, Jurkiewicz C, Phillips C, Sanders L, Soto M, Hackett P. Altitude Sickness Prevention with Ibuprofen Relative to Acetazolamide. Am J Med. 2019 Feb;132(2):247-251. doi: 10.1016/j.amjmed.2018.10.021. Epub 2018 Nov 10.
Results Reference
result

Learn more about this trial

Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy

We'll reach out to this number within 24 hrs